Despite the low tumor mutation burden in pulmonary lymphoepithelioma-like carcinoma tumors, the PD-L1 positivity of a majority of the tumors raises the potential of utilizing checkpoint immunotherapy as a treatment regimen that could benefit these patients. This evidence concerns the gene CD274 and carcinoma.